Oncology biotech Accent raises $75M to enter the clinic
Accent Therapeutics raised $75 million in Series C funding from three Big Pharma companies and other investors to test its first two precision oncology small molecules in early clinical trials.
The raise, led by global asset firm Mirae’s new US affiliate, which is dedicated to life sciences, occurred nearly four years after the startup disclosed a $63 million Series B in the early days of the pandemic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.